TRACON Pharmaceuticals

OverviewSuggest Edit

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. Its lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. The Company's other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. 
TypePublic
Founded2006
HQSan Diego, CA, US
Websitetraconpharma.com

Latest Updates

Employees (est.) (Dec 2018)26(+9%)
Revenue (FY, 2020)$0
Share Price (Jun 2021)$6.5
Cybersecurity ratingCMore

Key People/Management at TRACON Pharmaceuticals

Charles P. Theuer

Charles P. Theuer

President and CEO
Mark Wiggins

Mark Wiggins

Chief Business Officer
Bonne Adams

Bonne Adams

Executive Vice President
James Freddo

James Freddo

Chief Medical Officer
Scott B. Brown

Scott B. Brown

Chief Financial Officer
Dongliang Zhuang

Dongliang Zhuang

Vice President of Statistics and Bioinformatics
Show more

TRACON Pharmaceuticals Office Locations

TRACON Pharmaceuticals has an office in San Diego
San Diego, CA, US (HQ)
4350 La Jolla Village Dr
Show all (1)

TRACON Pharmaceuticals Financials and Metrics

TRACON Pharmaceuticals Revenue

USD

Net income (FY, 2020)

(16.8m)

EBIT (FY, 2020)

(16.2m)

Market capitalization (11-Jun-2021)

100.9m

Closing stock price (11-Jun-2021)

6.5

Cash (31-Dec-2020)

32.1m

EV

79.1m
TRACON Pharmaceuticals's current market capitalization is $100.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

7.9m3.4m8.8m3.0m

General and administrative expense

5.7m7.9m7.6m7.3m7.8m8.0m

R&D expense

25.7m21.6m19.4m30.5m14.5m8.2m

Operating expense total

31.4m29.4m27.0m37.7m22.3m16.2m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.1m4.2m1.2m1.2m807.0k815.0k626.0k631.0k7.5m3.0m

General and administrative expense

1.0m1.5m1.5m2.0m2.0m1.9m2.0m2.1m1.8m1.8m1.6m2.1m1.9m1.9m2.0m1.9m2.1m

R&D expense

3.8m5.4m5.9m5.5m6.8m4.5m5.6m4.9m4.3m9.4m8.1m7.0m5.2m4.3m3.1m2.0m2.2m

Operating expense total

4.8m6.9m7.4m7.5m8.8m6.4m7.5m7.0m6.1m11.2m9.7m9.1m7.2m6.2m5.1m3.9m4.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

41.4m35.7m29.5m25.1m16.4m32.1m

Accounts Receivable

9.4m

Prepaid Expenses

1.6m1.5m848.0k784.0k

Inventories

8.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(24.4m)(27.0m)(19.1m)(35.0m)(22.7m)(16.8m)

Depreciation and Amortization

94.0k48.0k28.0k22.0k12.0k

Accounts Payable

(2.2m)

Cash From Operating Activities

(27.1m)(13.2m)(30.8m)(23.6m)(17.0m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(4.0m)(6.9m)(13.4m)(6.5m)(14.8m)(20.7m)(7.1m)(13.7m)(12.5m)(8.4m)(18.1m)(27.2m)(7.2m)(13.5m)(18.7m)(4.0m)(8.5m)(5.1m)

Depreciation and Amortization

8.0k18.0k33.0k24.0k48.0k70.0k23.0k34.0k41.0k7.0k14.0k21.0k7.0k13.0k18.0k4.0k7.0k2.0k

Accounts Payable

490.0k3.1m3.9m

Cash From Operating Activities

(4.8m)(8.1m)(11.6m)(6.7m)(16.1m)(21.2m)(7.6m)(12.3m)(10.9m)(6.3m)(16.4m)(22.7m)(7.1m)(12.8m)(19.4m)(5.3m)(9.1m)(4.9m)
USDQ1, 2015

Financial Leverage

1.4 x
Show all financial metrics

TRACON Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

TRACON Pharmaceuticals Online and Social Media Presence

Embed Graph

TRACON Pharmaceuticals News and Updates

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the Company’s Phase 1 study of TJ004309 and Te…

TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partn…

TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partn…

TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual Meeting

Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma

TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to par…

TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies t…
Show more

TRACON Pharmaceuticals Blogs

TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Content Import Wed, 05/05/2021 - 16:06 TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update 05/05/21 This release is a…

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

SAN DIEGO , Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Content Import Wed, 01/06/2021 - 08:05 TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference 01/06/21 This release is a backfill fr…

TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering

TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering Content Import Tue, 12/29/2020 - 08:05 TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering 12/29/20 This release is a backfill from a News Wire General …

TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering

SAN DIEGO , Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Content Import Tue, 11/10/2020 - 16:03 TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update 11/10/20 This release is a…
Show more

TRACON Pharmaceuticals Frequently Asked Questions

  • When was TRACON Pharmaceuticals founded?

    TRACON Pharmaceuticals was founded in 2006.

  • Who are TRACON Pharmaceuticals key executives?

    TRACON Pharmaceuticals's key executives are Charles P. Theuer, Mark Wiggins and Bonne Adams.

  • How many employees does TRACON Pharmaceuticals have?

    TRACON Pharmaceuticals has 26 employees.

  • Who are TRACON Pharmaceuticals competitors?

    Competitors of TRACON Pharmaceuticals include SK Biopharmaceuticals, Prestige BioPharma and TOT BIOPHARM.

  • Where is TRACON Pharmaceuticals headquarters?

    TRACON Pharmaceuticals headquarters is located at 4350 La Jolla Village Dr, San Diego.

  • Where are TRACON Pharmaceuticals offices?

    TRACON Pharmaceuticals has an office in San Diego.

  • How many offices does TRACON Pharmaceuticals have?

    TRACON Pharmaceuticals has 1 office.